Insider Buying: HCW Biologics (NASDAQ:HCWB) CFO Purchases 14,235 Shares of Stock

HCW Biologics Inc. (NASDAQ:HCWB) CFO Rebecca Byam bought 14,235 shares of HCW Biologics stock in a transaction dated Friday, May 22nd. The stock was purchased at an average cost of $1.41 per share, with a total value of $20,071.35. Following the completion of the acquisition, the chief financial officer directly owned 57,245 shares in the company, valued at approximately $80,715.45. The trade was a 33.10% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

HCW Biologics Trading Down 26.0%

Shares of HCW Biologics stock traded down $0.68 on Wednesday, hitting $1.94. The stock had a trading volume of 3,330,455 shares, compared to its average volume of 36,091,248. HCW Biologics Inc. has a 52-week low of $0.25 and a 52-week high of $8.75. The stock has a market cap of $13.06 million, a price-to-earnings ratio of -0.21 and a beta of 1.13. The company’s 50 day moving average price is $0.72 and its 200 day moving average price is $1.15.

HCW Biologics (NASDAQ:HCWB) last posted its earnings results on Thursday, May 14th. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.81. HCW Biologics had a negative return on equity of 486.87% and a negative net margin of 34.73%.The business had revenue of $6.54 million during the quarter, compared to the consensus estimate of $6.54 million.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on HCWB shares. Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a report on Tuesday, April 21st. Wall Street Zen raised HCW Biologics to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, HCW Biologics currently has an average rating of “Hold” and an average price target of $35.00.

Institutional Trading of HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC acquired a new stake in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned about 9.15% of HCW Biologics as of its most recent SEC filing. Institutional investors own 2.96% of the company’s stock.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.